Markets
Bull
(CSA Images/Getty Images)

Bullish Snap analyst : “Will stabilize from here”

Deutsche Bank maintained its “buy” rating on the stock, but cut the price target.

As Snap endures a serious market beatdown Wednesday after posting earnings yesterday, bullish Deutsche Bank analysts maintained their “buy” rating on the stock, writing that they have confidence in the company’s strategic moves despite economic uncertainty created by President Trump’s trade war.

In particular, they spotlighted Snap’s growing SnapChat+ subscription service and momentum in its “direct response” advertising business. Direct response ads are a growth area of the ad industry, focused on digital ads that nudge viewers to take some sort of immediate action, like making a purchase or download.

Growth in direct response ads, Deutsche analysts wrote, will allow the company to boost ad sales to small and medium-sized businesses, diversifying the company’s client base. They wrote:

“While the company acknowledged that advertiser spending has been impacted by the macro environment, including some of those impacted by the changes to the de minimis trade exemption, we contend that Snap’s ad platform moving down funnel will help diversify toward an increasingly durable revenue mix, supported further by outsized [small and medium sized business] advertiser growth (up 60% y/y in 1Q), and continued strong growth at SnapChat+.

Overall, we think North American and EU daily active user trends will stabilize from here and we are positive on Snap’s ability to scale its direct response business, become more performant, drive greater adoption from SMB advertisers, and deliver greater revenue durability through subscriptions.

All in, we maintain our Buy rating, however lower our target price to $8.50 from $10.”

More Markets

See all Markets
markets

Spectrum owner Charter Communications is on pace for its worst day ever as broadband numbers and Q1 results disappoint

Cable and broadband company Charter Communications is on pace for its worst-ever trading day on Friday, as investors dump the stock following its Q1 results and forward guidance.

Charter, which owns Spectrum, reported adjusted earnings of $9.17 per share, below Wall Street estimates of $9.96 per share from analysts polled by FactSet. On the company’s earnings call, CFO Jessica Fischer appeared to lower its guidance for full-year revenue per user.

“It’ll be close either way in terms of whether we end up with net growth,” Fischer said.

The company lost 120,000 internet subscribers in the quarter, deeper than the expected 94,800 and double its loss from the same period last year. That news comes one day after Comcast’s earnings provided a bit of optimism for broadband as a category: the company reported Q1 losses of 65,000, significantly improving from 183,000 losses in the same quarter last year. Comcast is down more than 10%, on pace for its worst day since January 2025.

markets

Nvidia poised to snap longest run without a record close since the AI boom began

The stock price of the company responsible for the brains of the AI boom is finally showing some brawn again.

Nvidia, the world’s most valuable company, is poised to close at a record high for the first time since October 29, 2025, on Friday (if it ends above $207.04).

The AI chip trade is on fire, with the Philadelphia Semiconductor Index slated to deliver its 18th consecutive gain as Intel’s robust results and outlook juice the entire ecosystem. Hyperscalers report earnings next week, and their capex guidance can be thought of as the earnings guidance for Nvidia and other AI suppliers for the quarters to come.

This would end Nvidia’s longest stretch without a record close since the unofficial start of the AI boom (when the chip designer delivered blowout quarterly results in May 2023).

(Sorry if I jinx this!)

markets

Lilly slips after prescriptions for its weight-loss pill come in below expectations in second week

Eli Lilly fell on Friday after prescription data for its new weight-loss pill, Foundayo, showed that it’s having a significantly slower rollout than its top competitor.

The pill was prescribed about 3,700 times in its second week, according to IQVIA data cited by Deutsche Bank analysts, compared to the roughly 8,000 they were expecting. Novo Nordisk’s Wegovy pill, which came out in January, hit over 18,000 prescriptions in its second week.

The FDA approved Foundayo on April 1 and shipments began on April 9. Deutsche analysts noted that Lilly’s GLP-1 injections, which currently outsell Novo’s, also had a slower start.

Lilly fell more than 4% after the numbers were released. Novo Nordisk rose more than 5%.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, Robinhood Derivatives, LLC, or Robinhood Money, LLC. Futures and event contracts are offered through Robinhood Derivatives, LLC.